Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.